Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$39.50 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY Display this book on your site! Related Titles The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop Facing the Reality of Drug-Resistant Tuberculosis: Challenges and Potential Solutions in India: Summary of a Joint Workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research Other Related Titles Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary (2009) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix A: Agenda." Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary. Washington, DC: The National Academies Press, 2009. Please select a format: Page 113   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix A Agenda 8:00–8:10 Objectives of the Workshop   Gail Cassell, Eli Lilly and Company   Workshop Chair 8:10–9:40 Panel I: SETTING THE STAGE 10-minute presentations followed by a 30-minute panel discussion   Moderator: Kenneth Castro, Centers for Disease Control and Prevention   Paul Nunn, World Health Organization Global Incidence of MDR TB   Yanis Ben Amor, Earth Institute Underreported Threat of MDR TB in Africa   Gerald Friedland, Tugela Ferry Care and Research Collaboration HIV/MDR-XDR TB: Implications Megan Murray, Brigham and Women’s Hospital Number of MDR TB and XDR TB Patients Receiving Treatment Today: Successes/Failures/Consequences   Qian Gao, Shanghai Medical College Transmission of MDR TB Page 113 Front Matter (R1-R16) Summary (1-14) 1 Introduction (15-18) 2 The Global Spread of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis (19-34) 3 MDR TB Transmission, HIV Coinfection, and Transmission Control (35-50) 4 Diagnosis (51-58) 5 Infrastructure and Health Care Delivery Systems (59-66) 6 Global Systems for the Purchase and Delivery of TB Drugs (67-80) 7 Research on the Global Control of TB: Understanding the Role of Drugs, Vaccines, and Funding (81-96) 8 Strategies for Confronting the Global MDR and XDR TB Crisis (97-108) References (109-112) Appendix A: Agenda (113-116) Appendix B: Participant Biographies (117-138) Appendix C: Partners In Health White Paper - Stemming the Tide of Multidrug-Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic (139-236)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 113
Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge - Workshop Summary Appendix A Agenda 8:00–8:10 Objectives of the Workshop   Gail Cassell, Eli Lilly and Company   Workshop Chair 8:10–9:40 Panel I: SETTING THE STAGE 10-minute presentations followed by a 30-minute panel discussion   Moderator: Kenneth Castro, Centers for Disease Control and Prevention   Paul Nunn, World Health Organization Global Incidence of MDR TB   Yanis Ben Amor, Earth Institute Underreported Threat of MDR TB in Africa   Gerald Friedland, Tugela Ferry Care and Research Collaboration HIV/MDR-XDR TB: Implications Megan Murray, Brigham and Women’s Hospital Number of MDR TB and XDR TB Patients Receiving Treatment Today: Successes/Failures/Consequences   Qian Gao, Shanghai Medical College Transmission of MDR TB

OCR for page 114
Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge - Workshop Summary   Neel Gandhi, Tugela Ferry Care and Research Collaboration Transmission of XDR TB 9:40–9:50 Break 9:50–11:30 Panel II: HOW DID WE GET TO WHERE WE ARE TODAY: DIFFERENT PERSPECTIVES 10-minute presentations followed by a 40-minute panel discussion   Moderator: Richard Chaisson, Johns Hopkins University   Edward Nardell, Brigham and Women’s Hospital Lack of Infection Control   John Ridderhof, Centers for Disease Control and Prevention Laboratory Capacity: A Global Analysis   Anne Goldfeld, Harvard School of Public Health Drug and Health Care Delivery: Cambodian and Ethiopian Perspectives   Wieslaw Jakubowiak, WHO Country Office Russian Federation Fighting Drug Resistance in Russia: Challenges and Achievements   Paul Zintl, Partners In Health Drug Supply: The Stop TB Partnership Perspective   Ruth Levine, Center for Global Development Critical Role of Accurate Demand Forecasting: Lessons Learned from Malaria 11:30–12:30 Lunch 12:30–1:20 Keynote Address: The Research Path to Tuberculosis Control: An NIH Perspective   Anthony Fauci, National Institute of Allergy and Infectious Diseases 1:20–3:00 Panel III: ESSENTIAL BUILDING BLOCKS 10-minute presentations followed by a 20-minute panel discussion   Moderator: Leonard Sacks, Food and Drug Administration

OCR for page 115
Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge - Workshop Summary   Dale Nordenberg and Hamish Fraser, Brigham and Women’s Hospital Knowledge Management (IT): What Do We Need and What Do We Have?   David Persing, Cepheid, and Charles Daitch, Akonni Biosystems Point-of-Care Diagnostics: How Close Are We?   Ann Ginsberg, TB Alliance TB Drug Development: Realities of the Pipeline   Raymond Woosley, The Critical Path Institute Critical Path for Parallel Development of TB Point-of-Care Diagnostic and Drug Development   Jeff Moe, Duke University What Are the Odds? Who Will Pay? What Are the Incentives? 3:00–3:15 Break 3:15–4:15 Panel III: A BLUEPRINT FOR ACTION   Moderator: Peter Cegielski, Centers for Disease Control and Prevention   Salmaan Keshavjee, Partners In Health The Plan: From Powder to Patient   Discussants:   Michael Kimerling, Bill and Melinda Gates Foundation Carol Nacy, Sequella, Inc. Iain Richardson, Eli Lilly and Company Caroline Ryan, U.S. Department of State Sarita Shah, Tugela Ferry Care and Research Collaboration Alexander Sloutsky, University of Massachusetts Martie Van der Walt, Medical Research Council South Africa Charles Wells, Otsuka 4:15–5:30 Panel V: THE NEED FOR URGENCY 15-minute presentations followed by 45-minutes of discussion   Moderator: Jim Yong Kim, Partners In Health

OCR for page 116
Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge - Workshop Summary   Mark Harrington, Treatment Action Group Lessons from HIV   Paul Farmer, Partners In Health Lessons from MDR TB 5:30 SYNTHESIS AND NEXT STEPS   Gail Cassell, Eli Lilly and Company Workshop Chair